The tech\u00adnol\u00adogy com\u00adpany Laxxon Med\u00adical GmbH is set\u00adtling in Jena and will in future develop and man\u00adu\u00adfac\u00adture inno\u00adv\u00ada\u00adtive med\u00adi\u00adcines here on the basis of a spe\u00adcial 3D screen print\u00ading process. An addi\u00adtive man\u00adu\u00adfac\u00adtur\u00ading process enables the pro\u00adduc\u00adtion of multi-lay\u00adered phar\u00adma\u00adceu\u00adti\u00adcal appli\u00adca\u00adtion forms such as tablets. With this tech\u00adnol\u00adogy, tablets can be pro\u00advided with geo\u00admet\u00adric struc\u00adtures that enable the dis\u00adtri\u00adb\u00adu\u00adtion of one or more active phar\u00adma\u00adceu\u00adti\u00adcal ingre\u00addi\u00adents. This makes it pos\u00adsi\u00adble, for exam\u00adple, to achieve a delayed and, above all, con\u00adsis\u00adtent release of the active ingre\u00addi\u00adents in the body over a longer period of time. On the one hand, this serves to improve the effec\u00adtive\u00adness for the ben\u00ade\u00adfit of patients, and on the other hand, this patented process offers the phar\u00adma\u00adceu\u00adti\u00adcal indus\u00adtry com\u00adpletely new prod\u00aduct devel\u00adop\u00adment and man\u00adu\u00adfac\u00adtur\u00ading approaches.
\nThe 3D screen print\u00ading process has fur\u00adther advan\u00adtages: It enables both the pro\u00adduc\u00adtion of very small quan\u00adti\u00adties, as required in clin\u00adi\u00adcal research, for exam\u00adple, and the mass pro\u00adduc\u00adtion of med\u00adi\u00adcines nec\u00ades\u00adsary for the phar\u00adma\u00adceu\u00adti\u00adcal indus\u00adtry. In addi\u00adtion, this spe\u00adcial process makes it pos\u00adsi\u00adble to cre\u00adate a coun\u00adter\u00adfeit-proof \u201cwater\u00admark\u201d inside the tablet to pro\u00adtect against coun\u00adter\u00adfeit med\u00adi\u00adcines, some\u00adthing that has been impos\u00adsi\u00adble with con\u00adven\u00adtional man\u00adu\u00adfac\u00adtur\u00ading processes. This could be a sig\u00adnif\u00adi\u00adcant con\u00adtri\u00adbu\u00adtion to pro\u00adtec\u00adtion against coun\u00adter\u00adfeit med\u00adi\u00adcines. Coun\u00adter\u00adfeit med\u00adi\u00adcines not only rep\u00adre\u00adsent a con\u00adsid\u00ader\u00adable health risk for patients, they also cause annual dam\u00adage to the phar\u00adma\u00adceu\u00adti\u00adcal indus\u00adtry in Europe amount\u00ading to approx\u00adi\u00admately EUR 10 bil\u00adlion. In sum\u00admary, it can be said that Laxxon\u2019s 3D screen print\u00ading process has con\u00adsid\u00ader\u00adable poten\u00adtial to quickly achieve high mar\u00adket shares with the help of this inno\u00adva\u00adtion. The poten\u00adtial is jus\u00adti\u00adfied in par\u00adtic\u00adu\u00adlar by the fact that in the next 10 years more than 100 drugs with an annual sales vol\u00adume of USD 150 bn will lose their patent pro\u00adtec\u00adtion world\u00adwide. The inter\u00adest on the part of the indus\u00adtry to set itself apart from the com\u00adpe\u00adti\u00adtion through prod\u00aduct improve\u00adments is cor\u00adre\u00adspond\u00adingly high.<\/p>\n
bm\u2011t beteili\u00adgungs\u00adman\u00adage\u00adment th\u00fcrin\u00adgen gmbh (bm|t) has joined Laxxon Med\u00adical as lead investor through the Thuringian Start-up Fund (TSF) together with other pri\u00advate and insti\u00adtu\u00adtional investors. Kevin Reeder, Man\u00adag\u00ading Direc\u00adtor of bm|t, states: \u201cLaxxon\u2019s deci\u00adsion to choose Jena as the R&D nucleus for their extremely high-poten\u00adtial project con\u00adfirms the Thuringian uni\u00adver\u00adsity city as an excel\u00adlent tech\u00adno\u00adlog\u00adi\u00adcal loca\u00adtion. Laxxon and the 3D screen print\u00ading tech\u00adnol\u00adogy will sig\u00adnif\u00adi\u00adcantly strengthen Jena\u2019s tech\u00adnol\u00adogy and life sci\u00adence cluster.\u201d
\nThe man\u00adag\u00ading direc\u00adtors of Laxxon Med\u00adical GmbH, Prof. Dr. A. Schnee\u00adberger and K. K\u00fchne, are par\u00adtic\u00adu\u00adlarly pleased about the very good and direct coop\u00ader\u00ada\u00adtion oppor\u00adtu\u00adni\u00adties with the var\u00adi\u00adous inter\u00addis\u00adci\u00adpli\u00adnary insti\u00adtutes of the Uni\u00adver\u00adsity of Jena. Their know-how in poly\u00admer devel\u00adop\u00adment and mate\u00adri\u00adals research as well as their tech\u00adni\u00adcal equip\u00adment rep\u00adre\u00adsent a con\u00adsid\u00ader\u00adable loca\u00adtional advan\u00adtage for Laxxon, which was also a deci\u00adsive fac\u00adtor in the com\u00adpa\u00adny\u2019s deci\u00adsion to set\u00adtle here.<\/p>\n
Laxxon Med\u00adical GmbH, based in Jena, Ger\u00admany, is a sub\u00adsidiary of Laxxon Med\u00adical AG, domi\u00adciled in Zurich (CH), and a sis\u00adter com\u00adpany of Laxxon Med\u00adical Corp., domi\u00adciled in New York (USA). Laxxon Med\u00adical spe\u00adcialises in the prod\u00aduct devel\u00adop\u00adment and man\u00adu\u00adfac\u00adture of phar\u00adma\u00adceu\u00adti\u00adcals using the 3D screen print\u00ading process. The inter\u00adna\u00adtional phar\u00adma\u00adceu\u00adti\u00adcal mar\u00adket is to be addressed through these companies.<\/p>\n
bm|t, based in Erfurt, is a sub\u00adsidiary of the Th\u00fcringer Auf\u00adbaubank and the lead\u00ading address for invest\u00adments in Thuringia. The bm|t cur\u00adrently man\u00adages eight funds with a total vol\u00adume of around EUR 320 mil\u00adlion, which invest in inno\u00adv\u00ada\u00adtive com\u00adpa\u00adnies in almost all sec\u00adtors and in all phases of com\u00adpany devel\u00adop\u00adment \u2014 both in the start-up and growth phases or in com\u00adpany suc\u00adces\u00adsion situations.<\/p>\n